uniQure N.V.
LSE: 0EE0.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Matthew Craig Kapusta
- Employees
- 209
- Headquarters
- Amsterdam, Netherlands
- IPO year
- 2018
- Market cap
- $1.6B
- Website
- https://www.uniqure.com
Loading 0EE0…
Loading profile data…Frequently asked questions about 0EE0
What does uniQure N.V. (0EE0.L) do?
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
Where does 0EE0.L trade?
uniQure N.V. (0EE0.L) trades on the London Stock Exchange.
What sector is 0EE0.L in?
uniQure N.V. (0EE0.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of uniQure N.V.?
Matthew Craig Kapusta is the chief executive officer of uniQure N.V. (0EE0.L).
Where is uniQure N.V. headquartered?
uniQure N.V. is headquartered in Netherlands.
Does 0EE0.L pay a dividend?
uniQure N.V. (0EE0.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0EE0.L go public?
uniQure N.V. (0EE0.L) completed its initial public offering in 2018.